South San Francisco biotechnology teams often work under demanding scientific and operational conditions. A promising antibody may need to be humanized without losing important binding characteristics. A new target may require a fully human discovery program. A monoclonal antibody that performs well in a basic binding assay may still need functional screening before it can support a therapeutic, diagnostic, or translational objective.
Precision Antibody helps biotech and biopharmaceutical teams address these challenges through antibody humanization, fully human monoclonal antibody development, custom monoclonal antibody generation, functional screening, and antibody characterization. We design each project around the target, intended application, required data, and downstream development goals.
Our work is performed at our US laboratory in Columbia, Maryland. We serve South San Francisco and Bay Area organizations through direct scientific consultation, structured project milestones, data review, and coordinated delivery of project materials. We do not claim to operate a laboratory or office in South San Francisco.
For teams seeking antibody humanization services in South San Francisco, fully human antibody development in the Bay Area, or custom monoclonal antibodies for specialized applications, our objective is straightforward: develop and evaluate antibodies according to how they need to perform.
Precision Antibody was founded by scientists, run by scientists, and created for scientists. We are experts in antibody development, but what makes us different from all the other antibody development experts out there?
Precision Antibody’s founder Dr. Jun Hayashi is an accomplished Developmental Immunologist who has established the antibody development platform unique to the company. Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy.
Dr. Ginette Serrero, CEO is a Cancer Biologist with expertise in Biochemistry and target discovery which add basic understanding and solving of biological questions to the antibody development strategy. They have been working together and have had long and successful careers in Academia and Industry.
They lead Precision Antibody with a core team of Ph.Ds. with expertise in Immunology, Cancer Biology, Biochemistry, Molecular & Cell Biology, and Developmental Biology. Our team’s wide range of skills and knowledge allows us to understand your goal in the global biology context and enable us to provide professional guidance in designing and implementing a perfect project to successfully develop antibodies that will meet customer’s expectations.
Generating an antibody that recognizes an antigen is not always the same as developing an antibody that works in the intended application.
A clone may appear promising in a solid phase assay but perform differently when evaluated against a native cell surface target. An antibody with measurable binding may not provide the neutralizing, agonistic, internalizing, pairing, or matrix performance required by the program. Humanization may preserve some characteristics while changing others, making comparative expression and binding analysis important.
We begin by discussing the biology behind the project. This includes the target, antigen format, available starting materials, intended use, desired antibody characteristics, and the assays that will inform candidate selection.
South San Francisco has one of the densest biotechnology communities in the United States, with more than 250 biotech companies and a strong concentration of biopharmaceutical research and development organizations. These companies range from emerging venture backed teams to established organizations with dedicated discovery, translational, engineering, and preclinical groups.
The antibody needs within this ecosystem are equally varied. One company may have an established murine monoclonal antibody that requires humanization. Another may be beginning with a therapeutic target and need fully human antibody discovery. A third may need custom antibodies for pharmacokinetic studies, cell surface binding, internalization, neutralization, or diagnostic assay development.
We support these programs as an external scientific development partner. Our services can help teams access specialized antibody capabilities without building every immunization, hybridoma, expression, screening, characterization, and production workflow internally.
The intended application should influence how an antibody project is designed and evaluated.
For example, an antibody intended for flow cytometry may need to recognize a native antigen presented on a cell surface. An internalizing antibody program may require evidence that a candidate enters the target cell after binding. A neutralizing antibody program requires a functional readout that goes beyond antigen recognition. An anti idiotype program may need specific antibody pairs with suitable affinity, low dissociation rates, and limited serum interference.
Precision Antibody considers these requirements when developing the immunization and screening strategy. The exact approach depends on the target and project, but the goal remains consistent: provide information that helps the client select antibodies relevant to the intended use.
Depending on the project, relevant screening and characterization priorities may include:
Not every assay is appropriate for every program. We define the screening plan through scientific discussion so that the project remains aligned with the client’s actual decision criteria.
Antibody humanization is the process of modifying a nonhuman antibody sequence so that it contains a greater proportion of human antibody sequence while attempting to preserve the antigen recognition characteristics of the parental antibody.
Humanization may be considered when a program already has a murine or other nonhuman monoclonal antibody with useful specificity or functional activity. The objective is not simply to replace sequence regions. The resulting candidates must be expressed and evaluated so the development team can determine which designs retain suitable binding characteristics.
Humanization may help reduce the immunogenicity risk associated with nonhuman sequence content, but it does not guarantee the absence of an immune response. Immunogenicity is influenced by multiple molecular, product, patient, and treatment factors. Any therapeutic program requires appropriate additional assessment as it advances.
A humanization project begins with the parental antibody and its variable region information. The sequence, known binding behavior, antigen, desired human IgG subclass, and intended application help define the project.
Precision Antibody’s service includes humanization and optimization of the humanized sequence, synthesis of the resulting humanized VH and VL genes, expression of humanized antibodies, and verification of antigen binding parameters.
Rather than generating a single humanized design, our 5×5 Method produces 25 combinations. This provides a broader candidate set for comparative expression and binding evaluation.
The 5×5 Method applies five humanization techniques to the complementarity determining regions and framework regions of the heavy and light chain variable regions. The resulting designs are combined to create 25 humanized antibody combinations.
Each method addresses antibody sequence design from a different perspective. The purpose of using several approaches is to create multiple candidates that can be compared rather than depending on one theoretical design.
CDR grafting transfers the parental antibody’s complementarity determining regions into selected human antibody framework regions. The surrounding framework may influence how the binding loops are presented, so candidate evaluation remains important after the sequence has been designed and expressed.
Veneering focuses on replacing selected surface residues with human residues while retaining residues considered important to antibody structure and antigen recognition. This approach can reduce exposed nonhuman sequence content while seeking to preserve the parental antibody’s functional architecture.
Frankensteining uses human framework segments selected for compatibility with the parental antibody sequence. The method can combine framework elements rather than relying on a single intact human germline framework.
Specificity determining residue transfer focuses on residues considered particularly important to antigen recognition. This method aims to retain critical binding features while incorporating them into a more human sequence context.
Abbreviated CDR grafting uses a more focused definition of the residues transferred into the human framework. It provides another candidate design approach for evaluating the balance between human sequence content and retained antigen binding.
Sequence design is only one stage of a humanization project. A theoretically appropriate sequence must still be expressed and tested.
Precision Antibody’s humanization workflow includes:
Binding verification may be performed using enzyme immunoassay and Octet analysis. These results can help identify candidates that retain useful antigen recognition following humanization.
The preferred candidate can then be expressed using the desired human IgG subclass. Depending on the program, additional options may include transient expression, stable cell line development, production, and purification.
A humanization program can involve tradeoffs. A design with greater human sequence content may not always provide the same binding profile as the parental antibody. A candidate that expresses well may differ from one that shows the strongest binding. Framework selection may also influence structural stability and antigen interaction.
By expressing 25 combinations, the 5×5 Method provides a practical comparison set. This does not guarantee that every candidate will perform equally or that humanization will preserve every parental characteristic. It does, however, create multiple experimentally evaluated options for candidate selection.
This broader approach can be especially useful when:
The exact deliverables depend on the approved project scope. Available components include:
Precision Antibody states that all clones developed through the service are the customer’s property. We do not retain ownership. Confidentiality arrangements, including CDAs, NDAs, and MSAs, can be discussed as part of the project relationship.
The stated humanization timeline is approximately 60 days. Actual timing depends on the starting materials, sequence requirements, project scope, expression results, requested analyses, client decisions, and final deliverables.
A fully human monoclonal antibody development program begins with a target or immunogen and aims to generate antibodies with fully human IgG sequences. This route may be appropriate when a team does not already have a suitable parental antibody or wants to begin discovery with fully human candidates.
Precision Antibody provides fully human antibody development using Trans Chromosomics mouse technology. These TC mice are designed to generate antigen specific B cell populations and hybridomas that produce fully human IgG following immunization.
The TC mouse platform provides a different starting point from antibody humanization.
Humanization modifies an existing nonhuman antibody. Fully human discovery using TC mice generates new antigen specific antibodies through immunization and hybridoma development. The resulting program can produce multiple fully human IgG clones for screening and further evaluation.
Precision Antibody discusses each fully human program with the client’s scientific team from the beginning. Projects are organized around milestones and may incorporate application specific screening depending on the target and desired function.
A fully human monoclonal antibody program may involve:
Precision Antibody also offers related capabilities such as variable region sequencing using MiSeq, cell line development, antibody production up to gram quantities, anti idiotype antibody development for pharmacokinetic and antidrug antibody assays, and reverse engineering of human antibodies to create mouse monoclonal counterparts.
Fully human antibody development may be worth discussing when:
Precision Antibody states that fully human monoclonal antibody development can generate antigen specific clones producing fully human IgG in approximately 60 days. This is an estimated development timeline, not a universal guarantee. Antigen characteristics, immune response, screening complexity, functional requirements, sequencing, production scope, and project decisions can affect timing.
The choice between humanization and fully human discovery usually depends on the program’s starting point.
When a team already has a well characterized nonhuman antibody with valuable specificity or function, humanization may preserve the work invested in that parental clone. When a team begins with a target and needs new antibodies, fully human monoclonal development may provide a more appropriate discovery route.
Neither pathway is automatically better for every program. The target, existing data, desired functions, development stage, candidate diversity, timeline, and risk priorities should guide the decision.
Consideration | Antibody Humanization | Fully Human Development |
Typical starting point | Existing nonhuman antibody or variable region sequence | Target antigen or immunogen |
Primary objective | Increase human sequence content while evaluating retention of binding | Generate new antigen specific fully human IgG clones |
Precision Antibody approach | 5×5 Method producing 25 expressed combinations | Immunization and hybridoma development using TC mice |
Candidate output | Multiple humanized versions of an established parental antibody | Multiple newly generated fully human monoclonal antibodies |
Binding evaluation | EIA and Octet verification are included in the stated service | Screening is defined according to target and project scope |
Functional testing | Available when appropriate to the project | Available when appropriate to the project |
Stated timeline | Approximately 60 days | Approximately 60 days |
Suitable situation | A promising parental antibody already exists | The program begins with a target or needs new fully human leads |
Humanization may be the more direct path when the parental antibody already demonstrates valuable properties. The team may have binding data, functional data, a known epitope, or a substantial body of assay experience.
The project should still account for the possibility that sequence modification can affect binding, expression, or other characteristics. Expressing and evaluating multiple humanized candidates helps create an evidence based selection process.
Fully human discovery may be more suitable when the program has a compelling target but no established antibody. It may also be considered when the existing antibodies do not provide the required specificity, affinity, functional activity, or candidate diversity.
A consultation with our scientists can help clarify which route fits the available starting material and the program’s immediate decisions.
Not every antibody program begins with an existing clone or requires immediate humanization. Many projects need a custom monoclonal antibody developed around a particular antigen and application.
Precision Antibody customizes project strategies for therapeutic, diagnostic, bioanalytical, and research uses. Our broader custom antibody development services include mouse and rat monoclonal antibodies, fully human monoclonal antibodies, anti idiotype antibodies, and custom polyclonal antibody options.
Antigen and immunization decisions can affect the diversity and relevance of the resulting antibody response. A project involving a soluble protein may require a different strategy from one involving a cell surface receptor, small molecule, carbohydrate, lipid, nucleic acid, cleavage site, phosphorylation site, or conformational epitope.
Our scientists discuss the target biology and intended assay before establishing the project specification. This helps align the immunogen and screening strategy with the type of antibody the client needs.
Important project inputs may include:
Precision Antibody develops application specific mouse and rat monoclonal antibodies using project strategies tailored to the target and intended use.
The standard stated turnaround time is approximately 40 to 60 days. Actual timing may vary according to the immunogen, immune response, screening requirements, clone validation, and requested deliverables.
Custom monoclonal antibody projects may support:
Therapeutic antibody development requires the screening plan to reflect the desired biological activity. Binding is necessary, but it may not be sufficient for selecting a useful candidate.
A neutralizing antibody is intended to interfere with a biological interaction or activity, such as receptor ligand binding, pathogen entry, or another target dependent mechanism.
A neutralization program should use an assay that reflects the relevant biology as closely as the project permits. The assay design, controls, concentration range, and interpretation criteria should be discussed before screening begins.
Agonistic antibodies are developed to activate or stimulate a receptor mediated pathway. Candidate selection may require more than receptor binding because antibodies recognizing the same target can produce different functional outcomes.
The project should define the biological readout and desired response so that screening supports the intended mechanism.
Internalizing antibodies bind to a cell surface target and are taken into the cell. This property may be relevant to antibody drug conjugate research and other programs that depend on intracellular delivery after target binding.
Internalization must be evaluated experimentally. Recognition of a purified extracellular domain does not by itself establish that an antibody will bind the native target on cells or internalize effectively.
Precision Antibody can incorporate flow based screening and internalization assays when appropriate to the target and project scope.
Some targets present additional development challenges. They may be highly conserved, weakly immunogenic, conformationally sensitive, available only in limited quantities, or difficult to represent in a screening assay.
There is no universal solution for every difficult target. The project may require careful antigen design, alternative antigen formats, modified immunization strategies, cell based screening, or a broader candidate evaluation plan.
Early discussion is valuable because it allows the team to identify constraints before the project begins. It also helps establish realistic milestones and decision points.
Precision Antibody also develops anti idiotype antibodies that recognize the variable regions of drug antibodies.
Anti paratope antibodies compete with the target antigen for binding to the drug antibody. Anti idiotope antibodies recognize other determinants and do not necessarily interfere with antigen binding. Distinguishing these categories is important when designing assays for free, bound, or total circulating drug antibody.
For pharmacokinetic assay development, clients may need matched capture and detection antibodies. Relevant selection factors can include affinity, dissociation rate, pair compatibility, and serum interference. These characteristics should be evaluated according to the intended bioanalytical format.
Antibody characterization adds information that cannot be obtained from a basic endpoint binding result alone.
Precision Antibody provides biochemical, molecular, and biophysical characterization services that can support research and therapeutic development decisions. Available capabilities include isotyping, epitope mapping, sequencing, oligomer detection, antibody quantification, affinity ranking, antibody pairing, and full binding kinetic analysis.
Functional assays should be selected according to the question the project needs to answer.
A neutralization assay evaluates whether an antibody inhibits a defined biological interaction or activity. An internalization assay evaluates whether a target bound antibody enters the cell. Flow based assays can assess antibody recognition of native antigens on cells and can be useful for cell surface target programs.
These assays are project dependent. Their relevance depends on target expression, assay controls, available cell systems, and the intended mechanism.
Affinity is often discussed as a single value, but antibody antigen interactions also involve association and dissociation behavior. Two antibodies may have similar overall affinity while differing in how quickly they bind or how slowly they dissociate.
Real time, label free analysis can provide information about:
Precision Antibody uses Octet RED96 technology for label free binding analysis. Bio layer interferometry can support antibody screening, affinity based ranking, quantification, epitope binning, pairing, and full kinetic analysis.
Octet is also used within the stated humanization service to verify antigen binding parameters for expressed humanized candidates.
Biacore Based SPR Analysis
Precision Antibody provides Biacore surface plasmon resonance analysis for real time characterization of antibody antigen interactions. Depending on assay design, Biacore can provide detailed kinetic information that supports candidate comparison and assay development.
The choice between Octet and Biacore depends on the sample, interaction, throughput, assay format, and information required.
A development campaign may produce several antibodies that bind the target but recognize different or overlapping epitopes. Epitope binning can group candidates according to their competition patterns.
This information may help a team:
Epitope binning does not replace detailed epitope mapping, but it can be a useful part of candidate differentiation.
Every antibody development program is different, but a structured workflow helps maintain scientific and operational clarity.
We begin by discussing the target, available materials, intended application, desired antibody characteristics, and downstream plans.
For a humanization project, this may include parental sequence information and existing binding or functional data. For a fully human or custom monoclonal program, it may include the antigen, target biology, screening approach, and desired functions.
We prepare a project specification based on the discussion. The specification defines the applicable phases, activities, deliverables, and decision points.
Precision Antibody uses milestone based project management and invoicing. Data are provided at relevant stages so the client can review progress and make informed decisions about continuing to the next phase.
The scientific work proceeds according to the selected pathway.
This may involve:
Candidates are evaluated using the assays defined in the project. The purpose is to identify antibodies that meet the relevant binding, specificity, kinetic, or functional criteria.
When appropriate, culture supernatants from selected hybridoma clones may be provided for validation in the client’s assay.
Selected antibodies may advance into additional characterization, variable region sequencing, recombinant expression, stable cell line development, production, or purification.
The required scale depends on whether the material will support assay development, research studies, comparative testing, or another stage of the program.
Project data and agreed materials are delivered according to the scope. Selected hybridoma clones can be expanded, cryopreserved, and transferred.
All developed clones belong to the customer. Precision Antibody does not retain ownership. Confidentiality documentation can be established to support appropriate information exchange.
Biotechnology companies in South San Francisco operate within a highly active discovery and development environment. Programs move quickly, but the scientific decisions behind antibody generation, humanization, screening, and characterization still require careful attention.
Our role is to provide specialized antibody capabilities while giving the client visibility into the development process.
Precision Antibody was founded in 2000. Our scientific background includes immunology, cancer biology, cell biology, developmental biology, molecular biology, biochemistry, target discovery, and antibody development.
This breadth matters because an antibody project is not only a production exercise. Understanding the target and intended biological question can influence the antigen strategy, screening format, and candidate selection process.
We support South San Francisco clients remotely from our Columbia, Maryland laboratory. Project communication can include initial scientific discussions, project specification review, milestone updates, data sharing, and candidate selection conversations.
This model allows teams in South San Francisco, Oyster Point, the Peninsula, and the wider Bay Area to work with our antibody scientists without suggesting that laboratory work is performed locally.
Precision Antibody does not retain ownership of the clones developed for the customer. CDA, NDA, and MSA arrangements are available for appropriate project confidentiality and commercial terms.
For an early stage biotechnology company, clear ownership can be especially important when the antibody may become part of a research platform, diagnostic program, therapeutic pipeline, financing discussion, or partnership evaluation.
Our operations are performed at our facility in Columbia, Maryland. The laboratory is identified by Precision Antibody as AAALAC and OLAW accredited.
Keeping development activities within our US facility supports coordinated project execution, direct communication, and clear accountability for the work performed.
No. Precision Antibody serves biotechnology and biopharmaceutical organizations in South San Francisco, but our laboratory is located in Columbia, Maryland. Project work is completed at our US facility, with consultation, milestone communication, data review, and project coordination provided to Bay Area clients remotely.
Antibody humanization services modify a nonhuman antibody sequence to increase its human sequence content while seeking to preserve useful antigen recognition. Precision Antibody uses five humanization methods to create 25 expressed antibody combinations that can be evaluated for antigen binding.
The 5×5 Method applies CDR grafting, veneering, Frankensteining, SDR transfer, and abbreviated CDR grafting across the heavy and light chain variable regions. The resulting designs are combined to create 25 humanized antibody combinations for expression and binding evaluation.
Precision Antibody’s stated humanization service includes expression of 25 humanized antibody combinations. This provides multiple candidates for comparative evaluation rather than relying on one humanized design.
The humanization service includes verification of antigen binding parameters by enzyme immunoassay and Octet. Additional characterization or functional testing can be discussed according to the intended application and project scope.
A humanized antibody begins with an existing nonhuman antibody and is redesigned to contain a greater proportion of human sequence. A fully human antibody program begins with a target or immunogen and generates new antibodies with fully human IgG sequences. Precision Antibody uses TC mouse technology for fully human monoclonal antibody development.
Humanization may be appropriate when the program already has a valuable parental antibody with known specificity or function. Fully human discovery may be appropriate when the program begins with a target or needs a new pool of fully human candidates. The best route depends on the starting materials, data, target, desired functions, and program stage.
Precision Antibody lists an approximate 60 day timeline for its humanization service. The actual schedule depends on sequence inputs, design requirements, gene synthesis, expression, analytical scope, client review, and requested production services.
Precision Antibody lists an approximate 60 day timeline for generating antigen specific hybridoma clones producing fully human IgG using TC mice. Timing may change according to the target, immune response, screening plan, functional requirements, and downstream deliverables.
The standard stated turnaround range is approximately 40 to 60 days. The antigen, immunization response, clone screening, validation needs, and project complexity can affect the final timeline.
Yes. Precision Antibody offers screening and functional assay capabilities that include neutralization, internalization, and flow based assays. The appropriate assay must be defined according to the target, mechanism, cell system, and intended application.
Yes. Octet and Biacore services include confirmatory screening, antibody quantification, affinity based ranking, epitope binning, antibody pairing, full binding kinetic analysis, small molecule kinetics, and custom assays.
The developed clones belong to the customer. Precision Antibody does not retain ownership. Confidentiality and commercial agreements can be discussed before work begins.
Useful starting information may include the target, antigen format, existing antibody sequence or clone, intended application, desired functional activity, preferred antibody format, available assay controls, timeline priorities, and production requirements.
A project can still be discussed when some of these details are not yet available. The initial consultation can help identify what information is needed before the development plan is finalized.
A productive antibody program begins with a clear understanding of the target, the starting materials, and the decision the antibody must support.
Your team may need to humanize a promising parental antibody, generate fully human IgG candidates, create custom monoclonal antibodies against a challenging target, compare binding kinetics, or screen for a specific biological function. Precision Antibody can help define a project around those requirements.
Share your target information, existing antibody data, intended application, preferred format, functional priorities, and anticipated production needs with our scientific team. We will use that information to discuss the most appropriate development pathway, screening strategy, project milestones, and deliverables for your South San Francisco antibody program.
Precision Antibody™ is the forefront of the global Custom Antibody industry & it is led by the innovative minds in immunology and antibody development field.
